Gabelli Upgrades Boston Scientific (BSX) to Buy
More News related to BSX
- Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
- Boston Scientific (BSX) Announces Agreement with DoJ on Investigation of Guidant; Updates FY09 Outlook
- Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
- Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement
- Video: Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
More News related to Upgrades
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
- Adams Resources & Energy (AE) Announces Activity At Haynesville Shale
- NCI Building Systems (NCS) Announces Put Option Notification for 2.125% Convertible Senior Subordinated Notes
- Novartis (NVS) Acquires Majority Stake in Zhejiang Tianyuan Bio-Pharmaceutical for $125 Million
Gabelli upgrades Boston Scientific (NYSE: BSX) from Hold to Buy.
Shares of Boston Scientific are trading higher today amid the Gabelli upgrade and increased earnings estimates at JPMorgan. The stock most recently traded at $10.34, up 3.4% from yesterday's closing price.
To see all the analyst calls on Boston Scientific, visit our Analyst Ratings page.
Boston Scientific Corporation operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.
Related Categories
UpgradesStocks Mentioned
+0.23Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
